A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression - Concepedia

Concepedia

Publication | Closed Access

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

84

Citations

21

References

2009

Year

Estebán Martínez, J. A. Arranz, Daniel Podzamczer, Montserrat Loncà, José Sanz, Patricia Barragán, Esteban Ribera, Hernando Knobel, V. Roca, Félix Gutiérrez,

JAIDS Journal of Acquired Immune Deficiency Syndromes

Abstract

In HIV-1-infected patients with virological suppression, abacavir/lamivudine did not meet the noninferiority outcome for treatment efficacy compared with tenofovir/emtricitabine.

References

	Year	Citations

Page 1